{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:14:02Z","timestamp":1779236042783,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T00:00:00Z","timestamp":1487203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81077335"],"award-info":[{"award-number":["81077335"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["08ZR1411500"],"award-info":[{"award-number":["08ZR1411500"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["114119a1200"],"award-info":[{"award-number":["114119a1200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2017,7]]},"abstract":"Summary<\/jats:title>A proportion of chronic hepatitis B patients with normal or only minimally elevated alanine aminotransferase (ALT<\/jats:styled-content>) levels display significant histologic changes and would benefit from antiviral therapy. We aim to evaluate the histologic abnormalities seen in these patients and then determine which of them would most likely respond to peginterferon therapy. One hundred and thirteen hepatitis B e antigen (HB<\/jats:styled-content>eAg)\u2010positive patients with a normal or minimally elevated ALT<\/jats:styled-content> level and moderate\u2010to\u2010severe histologic changes in their liver tissue were selected to receive peginterferon monotherapy and participate in a follow\u2010up analysis. A multiple logistic regression analysis indicated that increasing age (P<\/jats:italic>=.049) and lower hepatitis B virus (HBV<\/jats:styled-content>) DNA<\/jats:styled-content> levels (P<\/jats:italic>=.038) were associated with significant histological abnormalities in patients with a normal or minimally elevated ALT<\/jats:styled-content>. Our predictive model which incorporated HB<\/jats:styled-content>eAg testing at treatment week 12 combined with hepatitis B surface antigen (HB<\/jats:styled-content>sAg) testing at treatment week 24 was able to identify which patients with a normal ALT<\/jats:styled-content> level would achieve a sustained virological response (SVR<\/jats:styled-content>) (positive predictive value [PPV<\/jats:styled-content>]: 66.7%, negative predictive value [NPV<\/jats:styled-content>]: 90.0%). Lower HB<\/jats:styled-content>sAg and HB<\/jats:styled-content>eAg levels at treatment week 24 were associated with a SVR<\/jats:styled-content> in patients with a minimally elevated ALT<\/jats:styled-content> level (PPV<\/jats:styled-content>: 100.0%, NPV<\/jats:styled-content>: 100.0%). A liver biopsy and antiviral therapy should be strongly considered when treating HB<\/jats:styled-content>eAg\u2010positive patients with a normal or minimally elevated ALT<\/jats:styled-content> level, low HBV DNA<\/jats:styled-content> level, and aged >35\u00a0years. On\u2010treatment quantification of combined HB<\/jats:styled-content>sAg and HB<\/jats:styled-content>eAg test results may be useful for predicting a SVR<\/jats:styled-content> to peginterferon monotherapy in these patients.<\/jats:p>","DOI":"10.1111\/jvh.12679","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T22:15:13Z","timestamp":1484950513000},"page":"573-579","source":"Crossref","is-referenced-by-count":10,"title":["Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen\u2010positive patients with normal or minimally elevated alanine aminotransferase levels"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5847-4888","authenticated-orcid":false,"given":"J.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Infectious Disease The Sixth People's Hospital affiliated with Shanghai Jiao Tong University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. R.","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Southeast Hospital affiliated with Xiamen University Zhangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease The Sixth People's Hospital affiliated with Shanghai Jiao Tong University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. W.","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease The Sixth People's Hospital affiliated with Shanghai Jiao Tong University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z. H.","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease The Sixth People's Hospital affiliated with Shanghai Jiao Tong University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Q.","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease The Sixth People's Hospital affiliated with Shanghai Jiao Tong University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009060"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/135965350601100614","article-title":"Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy","volume":"11","author":"Liaw YF","year":"2006","journal-title":"Antivir Ther"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300937"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.11.038"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078672"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.089722"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.03.006"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-012-9365-4"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.061"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21724"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032622"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/136.4.571"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605303342202"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23571"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05373-11"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.09.005"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23844"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32834ba13a"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12679","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:47:02Z","timestamp":1696225622000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,16]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/jvh.12679"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12679","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,16]]}}}